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The publication of studies undertaken in the last century to
characterize the role of tissue factor (TF) in physiological and
pathological processes has seen a sharp increase since 1987,
when the gene coding for human TF was sequenced and the
primary structure of the TF apoprotein deduced.1–4 Since
then, and until the beginning of the new century, the contri-
bution of TF to the atherothrombotic process was assessed
focusing on the vessel wall-derived TF, the only source of TF
believed at the time to be present in the human body. Then a
new player came onto the scene, the blood-borne TF, a term
originally introduced to allude mainly to circulating micro-
vesicles (MVs)-carrying TF, which can be taken up by circu-
lating platelets.5,6 This term now refers to TF present in the
circulation as a whole, whether it is derived from MVs, or
from activated leukocytes or platelets.
The ﬁndings that have established the role of vessel wall-
derived TF in atherothrombosis have been revised in several
reviews, which the reader is referred to.7–12 By contrast, the
pathophysiological relevance of the blood-borne TF is still a
matter of debate, and controversies on the presence of
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Abstract The contribution of vessel wall-derived tissue factor (TF) to atherothrombosis is well
established, whereas the pathophysiological relevance of the blood-borne TF is still a
matter of debate, and controversies on the presence of platelet-associated TF still exist.
In the past 15 years, several studies have documented the presence of TF in human
platelets, the capacity of human platelets to use TF mRNA to make de novo protein
synthesis, and the increase in the percentage of TF positive platelets in pathological
conditions such as coronary artery disease (CAD). The exposure of vessel wall-derived TF
at the site of vascular injury would play its main role in the initiation phase, whereas the
blood-borne TF carried by platelets would be involved in the propagation phase of
thrombus formation. More recent data indicate that megakaryocytes are committed to
release into the bloodstream a well-deﬁned number of TF-carrying platelets, which
represents only a fraction of the whole platelet population. These ﬁndings are in line
with the evidence that platelets are heterogeneous in their functions and only a subset
of them is involved in the hemostatic process. In this review we summarize the existing
knowledge on platelet associated TF and speculate on its relevance to physiology and to
atherothrombosis and CAD.
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platelet-associated TF still exists.13–17 In this review, we aim
to summarize the existing knowledge on platelet-associated
TF and to speculate on its relevance to physiology and to
atherothrombosis and coronary artery disease (CAD).
From Blood-Borne Tissue Factor to Platelet-
Associated Tissue Factor in Humans
Historical Background
Toward the end of the last century several studies provided
evidence for the presence of detectable blood-borne TF
activity in healthy subjects18–20 and for increased levels of
circulating TF antigen in patients suffering from cardiovascu-
lar disease,21–23 sepsis,24 hematologic disorders,19,25 and
disseminated intravascular coagulation.24,26 As a result, an
increased blood thrombogenicity in those disease states was
also described.27 At the same time, the ﬁrst articles reporting
the presence of procoagulant MVs in the circulating blood of
humans under normal and pathophysiological conditions
appeared in the literature.5,28–32 The presence of “TF–platelet
hybrids” were ﬁrst discovered and characterized in Yale
Nemerson’s laboratory by Giesen et al in 1999 and Rauch
and Nemerson in 2000: circulating platelets, carrying TF
through the fusion of TF-containing MVs with the membrane
of activated platelets through a CD15-P-selectin transfer
mechanism, may themselves trigger the activation of the
blood coagulation cascade.5,33 Based on these new ﬁndings
they also proposed a revised mechanism of thrombus forma-
tion foreseeing a concerted action of the two different pools
of TF: by this mechanism the exposure of vessel wall-derived
TF at the site of vascular injury would play its main role in the
initiation phase, whereas the blood-borne TF carried by
platelets would be involved in the propagation phase of
thrombus formation.5,6,33 The Nemerson group based the
need for an extra source of TF in thrombus formation on the
assumption that, as soon as platelets start to accumulate at
the site of injury, they hamper the interaction of the vessel
wall-derived TF with FVII and the activation of FIX and FX,
thus affecting the generation of the prothrombinase activity
on the surface of a growing thrombus.34 In this scenario, the
platelet-associated TF may therefore sustain the propagation
phase of thrombus formation.
Since then, several articles have reported the presence of
TF in human platelets. In 2001, Zillman et al observed by ﬂow
cytometry that a short (5 minutes) stimulation of whole
blood with collagen resulted in an increase of the quantity
of TF antigen associated with monocytes and granulocytes.35
The authors observed that when the amount of platelets in
whole blood was gradually reduced, the amount of TF on
leukocytes also decreased. Moreover, the increase in TF
antigen elicited by collagen was exclusively noted in the
CD41a-positive leukocytes, suggesting therefore that plate-
lets are a source of TF. It should be mentioned in this regard
that nowadays we are able to provide the demonstration of
this hypothesis taking advantage from the latest generation
ﬂow cytometers developed in recent years, which combine
the ﬂuorescence sensitivity of ﬂow cytometry with the
functional insights of high-resolution microscopy. Imaging
ﬂow cytometry allows us to characterize with absolute
precision the cell type that expresses TF. Taking advantage
from these tools it is possible to confer TF origin to one cell or
another, especially when leukocyte–platelet aggregates are
studied, performing awhole blood ﬂow cytometry analysis, a
method characterized by minimal sample handling (►Fig. 1).
In the following years, we and other investigators identiﬁed
TF antigen in human platelets from healthy subjects by using,
besides ﬂow cytometry, several other methodological
approach including western blotting, enzyme-linked immu-
nosorbent assays, confocal, and electronmicroscopy.36–38 The
most relevant ﬁnding of these studies was the observation
that stimulation of platelets with agonists such as adenosine
diphosphate (ADP), thrombin, epinephrine, thromboxane
analogue U46619, and calcium ionophore A23187 resulted
in the expression of TF, together with other commonmarkers
of platelet activation such as P-selectin or activated glycopro-
tein IIb/IIIa (GpIIb/IIIa), on the platelet membrane. This event
was time-dependent with the maximal expression of TF
observed 15 to 30 minutes after stimulation and was also
concentration-dependent.14,15,36,37 Moreover, in our experi-
mental setting,we also showed that the platelet-associated TF
was functionally active, being able to bind to FVIIa and to
trigger FXa and thrombin generation.37,39 We also provided
the evidence, for the ﬁrst time, that platelets contain the TF
mRNA.37,39 Thisﬁndingwas criticized at the beginning due to
the failure, by other investigators, to get the same results.35,40
Indeed, the presence of TF mRNA in platelets was seen as the
result of a leukocyte contamination during RNA preparation.
A few years later, two independent groups not only conﬁrmed
our ﬁnding, but they also showed that platelets, upon stimu-
lation, can use the TF mRNA to make de novo protein
synthesis.41,42
Since both platelets and TF are involved in the etiopatho-
genesis of many diseases, studies were performed to assess
the expression of platelet-associated TF in pathological con-
ditions such as coronary artery disease, diabetes, essential
thrombocythemia, and cancer.39,43–45
In the setting of CAD we showed that the number of
circulating TF-positive platelets and TF-positive platelet–
monocyte aggregates in patients with acute coronary syn-
drome (ACS) was signiﬁcantly higher than those found in
patients with stable angina and in healthy subjects.39 More-
over, we reported that the number of TF-positive platelets
was not only three times higher in ACS, but each platelet
expressed twice the number of TF molecules than in the two
other groups studied, so that the total capacity to generate
thrombin was greater. Thus, these ﬁndings suggest from one
side that TF-bearing platelets as well as platelet-leukocyte
aggregates may contribute to thrombus formation upon
plaque rupture providing a further explanation of the
increased cell thrombogenicity documented in ACS; from
the other side, TF-bearing platelets as well as platelet–
leukocyte aggregates might also be responsible of thrombus
generation in distal sites.
Moreover, the levels of TF mRNA in platelets from ACS
patients were also higher compared with those found in
patients with stable angina and in healthy subjects. This
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ﬁnding is of particular relevance considering the well-
described biosynthetic capacity of platelets.46–48
Several mechanisms may be responsible for the increased
number of TF-positive platelets observed in ACS patients,
including a higher amount of TF-positive platelets released by
megakaryocytes into the blood stream or de novo synthesis of
TF protein in the circulating platelets following splicing of the
TF pre-mRNA (see below and ►Fig. 2).39 Appropriate studies
however are required to test these hypotheses.
Mechanisms Responsible for the Presence of Tissue
Factor in Platelets: The Megakaryocyte-Platelet Axis
Data accumulated over the past 15 years suggest that at least
three mechanisms may be involved in the presence of TF in
platelets: (1) the MV-transfer mechanism; (2) the storage
within the α-granules and the open canalicular system, as
reported by Muller et al,38 and (3) the de novo protein
synthesis from the TF-speciﬁc messenger RNA.49 We believe
that these pathways are not mutually exclusive and one
mechanism may dominate over the other depending on the
pathophysiological conditions. Despite this evidence, it is still
commonly believed that the only mechanism responsible for
the presence of TF in platelets is through the uptake of TF-
positive microparticles released by activated endothelial cells
or leukocytes. We and others, however, have provided evi-
dence that not only human platelets, but also human mega-
karyocytes contain TF mRNA.37,39,41 Therefore, it can be
speculated that the TF mRNA and the protein detectable in
platelets could be the result not only of a MV-transfer
mechanism, but also of a direct transfer from megakaryo-
cytes.50 To test this hypothesis, we took advantage of an in
vitro cell culture model able to recapitulate megakaryocyte
differentiation and platelet biogenesis (Meg-01 megakaryo-
blast cell line), providing consistent evidence that TF is an
endogenously synthesized protein that characterizes mega-
karyocyte maturation. This in vitro approach allowed us to
study mRNA and protein expression in platelets in the
absence of any cross-talk with other cells or MVs. Indeed,
Fig. 1 Identiﬁcation of tissue factor (TF)-positive platelets by imaging ﬂow cytometry. Stimulation of whole blood with ADP (10 µM, 15 minutes)
results in an increased expression of platelet- and platelet–leukocyte aggregates (PLA)-associated TF. Single-cell analysis, performed on high-
resolution images of each cell in ﬂow by imaging ﬂow cytometry (FlowSight; Amnis, EMD Millipore, Billerica, MA), indicates that TF expression in
PLA is localized exclusively on platelets. A representative scatterplot of whole blood is reported in panel (A). Monocyte, granulocyte, and
lymphocyte populations were discriminated according to a physical parameter (side scatter, SSC) and CD45 expression. Platelets and PLA were
identiﬁed based on CD61 antigen expression. Representative brightﬁeld and CD61 (red)/CD45 (white)/Hoechst (magenta) composite images
(merge) are shown. Single cell images, representative of (B) TF-positive platelet; (C) TF-negative platelet; (D) TF-positive PLA; (E) TF-negative PLA
are shown. Images were acquired at 40 magniﬁcation. Channel images of Brightﬁeld (gray), TF (green), CD61 (red), CD45 (white), Hoechst
(magenta), and the composite image are reported as displayed by the Amnis IDEAS data analysis software. ADP, adenosine diphosphate.
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in these experimental conditions we showed the existence of
a direct transfer of both TF pre-mRNA and protein from
megakaryocytes to a subset of platelets where it contributes
to their thrombin generation capacity. Of interest, the per-
centage of TF-positive platelets that we observed in vitro
(both with Meg-platelets and with CD34þ-derived platelets)
was virtually identical to the amount found in blood from
healthy individuals. This striking data suggests that a ﬁnely
tuned mechanism, which deserves further investigation to
uncover the molecular pathways involved in its regulation, is
responsible for the controlled delivery of TF from megakar-
yocytes to platelets. All together these data support the
concept that, under physiological conditions, megakaryo-
cytes are committed to release into the bloodstream a well-
deﬁned and programmed number of TF-carrying platelets. It
can be speculated that under pathological conditions, such as
in the presence of low-grade inﬂammation as present in CAD
patients, alterations in the megakaryocyte transcriptome and
proteome as well as in the release of new platelets may occur.
Alternatively, mechanistic events may take place in the
bloodstream that drive TF pre-mRNA processing and de
novo protein synthesis (►Fig. 2). The common consequence
of these two hypothetical mechanisms is a higher number of
circulating TF-positive platelets.
Although further studies are needed to prove these
hypotheses in the context of CAD, we have recently observed
that in spontaneously hypertensive stroke-prone rats the
percentage of circulating TF-positive platelets directly corre-
lated with blood pressure and is the result of an increased
number of TF-positivemegakaryocyteswhich release into the
bloodstream a higher number of TF-positive platelets
(M. Camera, PhD, unpublished data, 2015).
Although platelets do not have a nucleus, they contain
about 2,000 to 7,000 transcripts.51–53 The ﬁnding that plate-
lets can use their mRNA pool to perform new protein synthe-
sis in response to cellular activation is of great importance,
since these mechanisms allow platelets to modify their
protein phenotype and, as a consequence, their functions.46
Concept of Platelet Heterogeneity: 30%— The “Magic”
Number
Leaving aside the controversy and giving credit to the fact that
TF is really present and functional in platelets, based on the
literature reviewed so far, we should also consider that TF is
Fig. 2 Hypothetical mechanisms involved in the regulation of the circulating levels of tissue factor (TF)-positive platelets under physiological and
pathological conditions. Under physiological conditions a percentage of TF expressing megakaryocytes are committed to release in the
bloodstream a constant number of platelets containing either TF protein or TF pre-mRNA.50 Under pathological conditions the increase in the
number of TF-positive platelets may be the result of a (A) mechanism taking place in the bloodstream and resulting in the splicing of the TF pre-
mRNA and de novo protein synthesis or (B) a mechanism taking place in the bone marrow inducing more megakaryocytes to express TF and to
release TF-positive platelets.
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one among the other coagulation factors, such as FV, FIX, FXI,
FXIII, ﬁbrinogen, FVII, exposed on the cell membrane upon
platelet activation. It is of interest to note that for some of
these factors, including TF, the presence not only of the
protein, but also of the speciﬁc pre-mRNA/mRNA has been
described and, as already mentioned, this is of particular
relevance taking into account the biosynthetic capacity of
platelets (►Table 1).37,41,42,54–59
It is well established that platelets play a key role in the
initiation and regulation of hemostasis and thrombosis.
Platelets adhere and aggregate at the site of vascular injury
to prevent blood loss and form the building blocks of a
thrombus; they also support the binding of the coagulation
factors involved in tenase and prothrombinase complex
(which results in thrombin generation and further platelet
activation) to localize, amplify, and control the burst of
thrombin generation at the injury site thus preventing a
systemic activation of the blood coagulation.60,61
Although this function has been historically ascribed to all
platelets, it is important to underline that much evidence
accumulated in the past years indicate that platelets are
heterogeneous in their functions and only a subset of platelets
is involved in the hemostatic process.61,62 Themechanisms of
origin and function of this heterogeneity is still unclear.
Indeed, as a matter of fact, individual platelets differently
respond to agonists like collagen or thrombin resulting in a
different binding capacity to coagulation factors and other
plasma proteins. As examples in support to this concept, the
platelet phospholipid asymmetry and the platelet-derived
pool of FV will be brieﬂy discussed.
Phospholipids containing choline, such as sphingomye-
lin and phosphatidylcholine are the main components of
the outer surface of plasma membranes of all eukaryotic
cells under resting conditions, while phosphatidylserine
and phosphatidylethanolamine are localized on the inner
surface.63,64 In this conformation, the platelet membrane
provides a nonprocoagulant surface.65 Upon platelet acti-
vation theﬂip–ﬂopmechanism, catalyzed by speciﬁc trans-
locases,66 allows an enhanced expression of negatively
charged phosphatidylserine in the outer membrane leaﬂet,
conferring to platelets the procoagulant surface necessary
for the assembly and activation of several enzyme com-
plexes of the coagulation process.60,67,68 It is important to
consider in this regard that, when platelet from healthy
subjects are activated by physiological concentrations of
agonists such as thrombin, collagen, or by the combined
action of thrombin and collagen the exposure of phospha-
tidylserine occurs only in a fraction of activated platelets
that ranges from approximately 4 to 30%, at most, depend-
ing to the agonist used.69–71 These data clearly highlight the
fact that only a subset of the activated platelets undergoes
phosphatidylserine exposure on the membrane surface to
sustain the hemostatic process.
Thrombin generation occurs via prothrombinase, a stoi-
chiometric complex of the cofactor FVa and the serine prote-
ase FXa, assembled on a phosphatidylserine-exposing
membrane surface in the presence of calcium.72 FV exists in
two pools in whole blood: 80% is in the plasma and 20% is
stored in platelet α-granules. The α-granules stored FV is
directly derived from megakaryocytes through endocyto-
sis.73,74 To understand the physiological role of the α-gran-
ules stored FV as compared with the plasma FV, it has been
calculated that the nominal FV concentration of platelets
exceeds that of plasma by an approximate factor of 100.
Thus, its release from α-granules could provide a high local
concentration of FV that may be critical for the generation of
platelet prothrombinase activity.75 In 2010, Fager et al pub-
lished the evidence that only a fraction, about 30%, of
activated platelets expressing P-selectin do also express FV,
and in the same experimental conditions only a fraction of
activated platelets do bind to FXa. These data support the
concept that the ability of activated platelets to generate
thrombin via prothrombinase is deﬁned, once again, only
by a subpopulation of platelets expressing both nondissoci-
able and dissociable pools of platelet-derived FVa, each
capable of binding FXa, and expressing an increased density
of adhesive receptors, including P-selectin, at their activated
membrane surface.76
Table 1 Coagulation factors present in platelets
Coagulation factor Protein mRNA References for mRNA
Tissue factor þ þ 37,39,41,42
FV þ Not reported
FVII þ Not reported
FIX þ Not reported
FXI þ þ 59
FXIII þ þ 54,55, and M. Camera, PhD, unpublished data, 2015
Fibrinogen þ not reported
vWF þ þ 56 and M. Camera, PhD, unpublished data, 2015
TFPI þ þ 57 and M. Camera, PhD, unpublished data, 2015
Protein S þ þ 58
Abbreviation: F, factor.
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Similarly towhat described for phosphatidylserine and FV,
also TF is expressed only by a fraction of platelets. As shown
in ►Fig. 3, ﬂow cytometry analysis of thrombin receptor
activating peptide 6 (TRAP-6) or ADP-stimulated platelets
from healthy subjects shows that the expression of activated
GpIIb/IIIa, of P-selectin and of TF occurs in about 80, 50, and
30% of platelets, respectively. A similar trend was observed
when other platelet agonists, such as collagen or thrombox-
ane A2, were used. These observations ﬁt particularly well
with the in vivo evidences published by Stalker et al who
reported that platelet activation is not uniform throughout
the hemostatic plug.77 They found that the hemostatic
response produces an organized structure, composed of
activated platelets interspersed with ﬁbrin, characterized
by a regional heterogeneity due to differences in platelet
activation state, packing density, and stability. Indeed, a core
of fully activated platelets, expressing P-selectin and sustain-
ing thrombin generation, is overlaid with an unstable shell of
less activated, P-selectin negative, platelets. It is noteworthy,
in this regard, that when costaining for TF and P-selectin is
performed on in vitro agonist stimulated human platelets,
ﬂow cytometry, and confocal microscopy analysis indicate
that all the TF-positive platelets also express P-selectin
(►Fig. 4).15 Moreover, the fact that in vitro data show a
colocalization between TF and FV (►Fig. 4) unequivocally
combines the discoveries made by different research groups
in the past years. All together these data strongly support the
in vivo hemostatic plug model reported by Stalker et al,
according to which the thrombin generation capacity is
restricted to the platelets composing the core of the plug,77
and theyalso give further credit to the theory proposed by the
Nemerson group 15 years ago.6,34
Electron microscopy analysis of thrombi formed in vivo
published in the 1960s provided the ﬁrst evidence for the
presence of a heterogeneous platelet activation within
the thrombus.78–80 More recently, Palmerini et al assessed
the presence of coagulant active TF in coronary thrombi
collected from patients with ST-segment elevation acute
Fig. 3 Heterogeneity of platelet response to agonist stimulation. In vitro platelet activation results in a differential expression of the common
markers of platelet activation, such as tissue factor, P-selectin or activated glycoprotein IIb/IIIa (GpIIb/IIIa), identifying different platelet
subpopulations. While almost all stimulated platelets express activated GpIIb/IIIa upon stimulation, only a subset of platelets expresses P-selectin
and tissue factor (50 and 30%, respectively). Whole blood from healthy subjects, left untreated (resting) or stimulated with TRAP-6 (5 µM) or ADP
(10 µM) for 15 minutes, was incubated with saturating concentration of mouse anti-activated GpIIb/IIIa-FITC (PAC-1 monoclonal antibody, Becton
Dickinson, Sparks, MD) anti-P-selectin-APC (monoclonal antibody against CD62, Becton Dickinson) or anti-TF-FITC (monoclonal antibody against
TF, catalogue no. 4508, American Diagnostica, Lexington, MA) and mouse anti-CD41-PE MoAbs. FITC-, APC-, and PE-conjugated isotype controls
were used in all the experiments to quantify the background labeling. Representative density plots of three independent experiments are
reported in the ﬁgure. The mean value of the results is reported as percentage positive events  standard deviation. ADP, adenosine diphosphate;
TRAP-6, thrombin receptor activating peptide 6.
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myocardial infarction (STEMI), showing that functionally
active TF accumulates at sites of thrombus formation in the
acute phase of STEMI; the TF activity was indeed speciﬁcally
inhibited byamonoclonal antibody able to block TF-mediated
coagulation activity.81 Although, as stated by the authors, the
study was not designed to assess the source of TF found in
thrombi, Palmerini et al showed very clearly that, in a human
setting, also platelets, besides inﬂammatory cells within the
thrombus of STEMI patients, stain positively for TF. These
ﬁndings conﬁrm leukocytes as source of TF, but they also
support the evidence that platelets may be another source of
TF. Of note, the TF immunolocalization provided by Palmerini
et al highlights that not all platelets within the thrombus
express TF. These data completelymatchwith the evidence, as
already stated above, that not all circulating platelets, both in
healthy subjects as well as in patients with CAD, express TF
when analyzed by ﬂow cytometry.37,39
Species-Speciﬁc Differences in Platelet
Tissue Factor Expression
The dispute centered on platelet-associated TF has also
been fueled over time by the fact that the evaluation of
the expression of platelet-associated TF in mice provided
negative results. By contrast, compelling evidence supports
the presence of TF in rat platelets. Indeed, in 2012 Hernán-
dez Vera et al showed, through an immunological approach,
the presence of functionally active TF in rat platelets.82
More recently, Tyagi et al not only provided the evidence,
using a proteomic approach, that exposure of rats to a
hypoxic stimulus results in an upregulation of platelet-
associated TF expression but they also showed that plate-
lets contain TF pre-mRNA which is processed, upon expo-
sure to hypoxia, to form themature TFmRNA.82,83Whether
the negative results in mice and the positive results in rats
are a matter of species speciﬁcity or a methodological issue
remains to be addressed. It should be mentioned, however,
that important cross-species differences in mammalian
coagulation systems have been previously reported.84,85
Moreover, although several antibodies able to recognize
different epitopes of the human TF protein have been
developed and are commercially available, much more
limited is the availability of antibodies directed against
mouse TF.86 Finally, it is worth mentioning that TF protein
was also observed in platelets from pigs. Of interest,
platelets from ovariectomized pigs treated with 17β-
Fig. 4 Colocalization of tissue factor (TF) and coagulation factor V (FV) or P-selectin on the surface of activated platelet. Platelets expressing TF
upon agonist stimulation do also express FV and P-selectin. Whole blood was stimulated in vitro with TRAP-6 (5 µM, 15 minutes) and labeled for TF
and coagulation FV ( Alexa Fluor 647 labeledmonoclonal antibody against FV, Enzyme Research, Life Technologies, Grand Island, NY) or P-selectin.
The representative density plots of three independent experiments reported in the ﬁgure show the colocalization of TF with coagulation FV
(12  8%) or with P-selectin (20  5%). TRAP-6, thrombin receptor activating peptide 6.
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estradiol or with raloxifene showed increased TF levels
compared with untreated pigs.87
Conclusions and Future Directions
Although the concept of platelet-associated TF has not been
completely accepted so far in the ﬁeld of hemostasis and
thrombosis, the evidence of its presence and its potential
involvement in the hemostatic and thrombotic processes
both in humans and in experimental animal models, has
accumulated in the past 15 years.37,38,43–45 In one hand, the
evidence of the present time suggests that the function of
platelet-associated TF is to support thrombus growth, as ﬁrst
postulated by the Nemerson group, in the setting of a plaque
rupture with thrombotic occlusion.6,34 On the other hand,
platelet-associated TF could play a key role also in venous
thrombosis and in immune defense where activation of
platelets and the coagulation cascade take place in the
absence of endothelial injury and, therefore, in the absence
of the contribution of the vesselwall-derived TF.88,89 The next
chapter of the evolving story of platelet-associated TF will
include the identiﬁcation of the molecular mechanisms
involved in its overexpression in pathological conditions.
Such mechanisms should allow for the development of new
therapeutic strategies aimed to the prevention of thrombotic
complications in cardiovascular diseases.
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